The invention relates to a mixture of human milk oligosaccharides that consists essentially of: LNnT, LNT, 2′-FL, 3′-SL, 6′-SL, either DFL or 3-FL, preferably DFL, useful for preventing and/or treating viral and/or bacterial infections in a non-infant human.
The present invention concerns a method for separating different oligosaccharides having at least one carboxylic acid group by contacting them with basic anion exchange resins.
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01J 41/07 - Processes using organic exchangers in the weakly basic form
Disclosed herein are systems and methods for the purification of human milk oligosaccharides (HMOs). The HMOs can be purified from a suspension containing one or more of a bacterial biomass, cell fragments, small particles, and biomolecules. Advantageously, the solution can be pre-treated prior to centrifuging to form a clarified supernatant containing purified HMOs.
The present invention relates to the field of recombinant production of biological molecules in genetically modified cells. More particularly, it relates to a method for recombinant production of sialylated human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS), the protein expressed being Fred.
C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
C07K 14/24 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
The present invention relates to a genetically modified cell expressing an α-1,2-fucosyltransferase and an α-1,3-fucosyltransferase, and a transporter protein of the major facilitator superfamily (MFS) and to a method for recombinant production of human milk oligosaccharides (HMOs) using said genetically modified cell. More particularly, the invention provides a method for recombinant production of and a genetically modified cell capable of producing difucosyllactose (DFL) as the most abundant HMO, with a relatively low content of 3-fucosyllactose (3FL) and/or 2′-fucosyllactose (2′FL).
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
The present invention relates to fucosylated human milk oligosaccharides for improving sleep maturation, for example improving trouble sleeping, in a non-infant.
The application relates to compositions containing 2′-FL and DFL for use in a method of reducing pain and/or the perception of visceral pain in a non-infant human.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
The present invention relates to the field of recombinant production of biological molecules in host cells. More particularly it relates to a method for recombinant production of human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS).
C12P 19/00 - Preparation of compounds containing saccharide radicals
C07K 14/24 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic encoding a putative transporter protein of the MFS superfamily; and methods using said cell for the production of oligosaccharide(s), preferably an HMO.
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C07K 14/24 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
11.
METHODS FOR PROVIDING A SOLID HMO PRODUCT, AND SOLID HMO PRODUCTS OBTAINED THEREBY
Various methods are provided for providing a solid HMO product, said methods including drum-drying, belt drying, preferably vacuum bed drying, or granulation. Solid HMO products are obtained via said methods, as well as solid HMO products per se. The methods can provide solid HMO products which are different to those achieved via other methods.
A23C 9/20 - Dietetic milk products not covered by groups
C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
F26B 5/12 - Drying solid materials or objects by processes not involving the application of heat by suction
F26B 15/18 - Machines or apparatus for drying objects with progressive movementMachines or apparatus with progressive movement for drying batches of material in compact form with movement in a path composed of one or more straight lines, e.g. compound the lines being all horizontal or slightly inclined the objects or batches of materials being carried by endless belts
A23C 1/03 - Drying in thin layers on drums or rollers
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A23P 10/22 - Agglomeration or granulation with pulverisation of solid particles, e.g. in a free-falling curtain
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
A23C 9/146 - Milk preparationsMilk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by ion-exchange
A23C 9/142 - Milk preparationsMilk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
12.
SYNTHETIC COMPOSITION FOR TREATING METABOLIC DISORDERS
A method for treating metabolic disorders includes determining a treatment group comprising obese non-infant humans; formulating a composition comprising one or more synthetic non-fucosylated human milk oligosaccharides (HMOs) selected from lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and/or 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), and lacto-N-fucopentaose I (LNFP-I), that are effective for: increasing in the gastrointestinal microbiota of a non-infant human during a treatment period, the relative abundance of Bifidobacterium adolescentis and reducing a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage; and reducing the precursor condition in at least one non-infant human in the treatment group by providing the composition to the at least one non-infant human during the treatment period.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 9/00 - Medicinal preparations characterised by special physical form
The invention relates to a method for selective crystallization of 2′-FL from an aqueous solution comprising 2′-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution.
The present invention relates to the field of recombinant production of biological molecules in genetically modified cells. More particularly, it relates to a method for recombinant production of human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS), the protein expressed being Fred.
The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic acid encoding a protein of the MFS superfamily; and methods using said cell for the production the oligosaccharide, preferably an HMO.
C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
C07K 14/24 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
16.
Amorphous mixture comprising a neutral mono- or oligosaccharide and an acidic non-carbohydrate component
It is provided i) an amorphous carbohydrate with improved chemical stability and/or physical features, ii) a method for producing an amorphous carbohydrate with improved chemical stability and/or physical features, and iii) a method for improving the chemical stability and/or the physical features of an amorphous carbohydrate.
It is provided i) an amorphous carbohydrate with improved chemical stability and/or physical features, ii) a method for producing an amorphous carbohydrate with improved chemical stability and/or physical features, and iii) a method for improving the chemical stability and/or the physical features of an amorphous carbohydrate.
The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic acid encoding a protein of the MFS superfamily; and methods using said cell for the production the oligosaccharide, preferably an HMO.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
19.
SEPARATION OF SIALYLATED OLIGOSACCHARIDES FROM FERMENTATION BROTH
The present invention relates to the separation and isolation of sialylated human milk oligosaccharides (HMOs) from the reaction mixture in which they are produced.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.
The invention relates to a human milk oligosaccharide (HMO) for use in supplementing the diet of a pregnant woman, a synthetic composition comprising an HMO for use in supplementing the diet of a pregnant woman, and a method for improving health outcomes in an infant by supplementing the diet of a pregnant woman.
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 37/00 - Drugs for immunological or allergic disorders
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in a lac-tose-intolerant, IBS patient; reintroducing a source of lactose into the diet of a lactose-intolerant, IBS patient while prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in the IBS patient; and/or reducing the severity and/or occurrence of non-gastrointestinal symptoms in a lactose-intolerant, IBS patient.
A synthetic mixture of human milk oligosaccharides (HMOs) consisting essentially of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), 2′-fucosyllactose (2′FL), 3′-O-sialyllactose (3′-SL), 6′-O-sialyllactose (6′-SL) either difucosyllactose (DFL) or 3-fucosyllactose (3-FL), preferably DFL, and optionally lactose. Said synthetic composition is useful for: treating or preventing viral and/or bacterial infection in a non-infant human; modulating the microbiota of a non-infant human; and/or improving the cognitive function of a non-infant human and as a pharmaceutical or nutritional composition.
A mixture of human milk oligosaccharides that comprises or consists essentially of a) LNTri II, LNT, pLNH II and optionally lactose, or b) LNTri II, LNnT, pLNnH and optionally lactose, and is useful for preventing or treating viral or bacterial, intestinal and respiratory infections and for modulating the human gastrointestinal microbiota to increase Bifidobacterium abundance. A process for preparing the mixture and methods of crystallizing LNnT and LNT is also described.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
C07H 1/00 - Processes for the preparation of sugar derivatives
25.
SYNTHETIC COMPOSITION FOR BALANCING THE BILE ACID PROFILE IN THE INTESTINE
This invention relates to a method and composition for balancing the bile acid profile in the intestine of humans, particularly decreasing primary bile acids and/or increasing production of secondary bile acids.
The present invention relates to the separation and isolation of neutral human milk oligosaccharides (HMOs) from the reaction mixture in which they are produced.
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
C12P 19/26 - Preparation of nitrogen-containing carbohydrates
28.
SYNTHESIS OF THE FUCOSYLATED OLIGOSACCHARIDE LNFP-V
The present invention provides a method for biotechnological production of LNFP-V by using recombinant bacterial cells. LNFP-V is produced by using a polypeptide having an a1,3/4-fucosyl transferase activity and comprising or consisting of an amino acid sequence that has a sequence identity of at least 90% with amino acid sequence of SEQ ID No. 1 or 3.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
29.
NUCLEIC ACID CONSTRUCT COMPRISING 5' UTR STEM-LOOP FOR IN VITRO AND IN VIVO GENE EXPRESSION
The present invention relates to the field of recombinant production of biological molecules in host cells. The invention provides nucleic acid constructs that allow to modify expression of a desired gene using both in vitro and in vivo gene expression systems with optimized stem-loop structures in the 5′ UTR of said genes. The constructs can advantageously be used to produce a variety of biological molecules recombinantly in industrial scales, e.g. human milk oligosaccharides (HMOs)
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing, managing or treating postdrome symptoms of migraine, and/or abdominal migraine, and/or the secondary prevention of stress/anxiety induced migraine.
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for prophylactically reducing symptom severity and/or occurrence in a non-coeliac wheat and/or gluten sensitivity patient, and for reducing the severity and/or occurrence of non-gastrointestinal symptoms in the patient.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
The invention relates to a genetically modified microorganism for making a oligosaccharide, preferably of 3-8 monosaccharide units, more preferably of 3-5 monosaccharide units, particularly a HMO, which comprises one or more genes encoding a sucrose utilization system, so the microorganism can use sucrose as a carbon and energy source.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
A method for reducing nociceptive sensitivity in non-infant humans includes in some examples selecting a non-infant human experiencing a condition and associated nociceptive sensitivity (e.g., irritable bowel syndrome or chronic neuropathic pain). In such examples, the method further includes selecting an effective amount of one or more human milk oligosaccharides (“HMOs”) chosen from the group consisting of 6′-sialyllactose (6′-SL), and a mixture of 6′-SL and lacto-N-tetraose (LNT) and reducing the nociceptive sensitivity by administering the selected effective amount of the chosen HMOs to the non-infant human during an initial phase. In some examples, the method includes activating GPR35 receptors by administering the effective amount of the chosen one or more HMOs. In some examples, the HMOs are a mixture of 6′-SL and LNT that provides a synergistic effect relative to each of the 6′-SL and LNT alone.
The present invention relates to the field of recombinant production of biological molecules in genetically modified cells. More particularly, it relates to a method for recombinant production of sialylated human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS), the protein expressed being Fred.
The present invention relates to a genetically modified cell expressing an α-1,2-fucosyltransferase and an α-1,3-fucosyltransferase, and a transporter protein of the major facilitator superfamily (MFS) and to a method for recombinant production of human milk oligosaccharides (HMOs) using said genetically modified cell. More particularly, the invention provides a method for recombinant production of and a genetically modified cell capable of producing difucosyllactose (DFL) as the most abundant HMO, with a relatively low content of 3-fucosyllactose (3FL) and/or 2'-fucosyllactose (2'FL).
The present invention concerns a method for separating different oligosaccharides having at least one carboxylic acid group, also referred to as charged oligosaccharides. The method allows for the high throughput separation of oligosaccharides that are otherwise difficult to separate in non-chromatographic methods and involves the use of a weakly basic macroporous anion exchange resin.
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01J 41/07 - Processes using organic exchangers in the weakly basic form
C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
Disclosed herein are systems and methods for the purification of human milk oligosaccharides (HMOs). The HMOs can be purified from a suspension containing one or more of a bacterial biomass, cell fragments, small particles, and biomolecules. Advantageously, the solution can be pre-treated prior to centrifuging to form a clarified supernatant containing purified HMOs.
The invention relates to crystalline polymorphs of lacto-N-tetraose (LNT) and methods for making the same for use in pharmaceutical compositions, nutritional formulations and food supplements.
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
The present invention relates to fucosylated human milk oligosaccharides for improving sleep maturation, for example improving trouble sleeping, in a non-infant.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A61P 25/00 - Drugs for disorders of the nervous system
40.
HUMAN MILK OLIGOSACCHARIDES FOR USE IN SUPPORTING NIGHT SLEEP DURATION
This invention relates to human milk oligosaccharides (HMOs) for use in a non-infants to support better sleep quality and improve night sleep duration.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
41.
HUMAN MILK OLIGOSACCHARIDES FOR USE IN ENHANCING EXECUTIVE FUNCTION
Use of a human milk oligosaccharide (HMO), or a nutritional composition comprising a human milk oligosaccharide, to enhance executive function in a non-infant, to prevent and/or reduce the risk of sub-optimal executive function in a non-infant, to manage sub-optimal executive functioning in a non-infant, and/or to improve myelination to mature the pre-frontal cortex region of the brain in a non-infant, as well as synthetic compositions of HMOs and packs comprising at least 14 individual daily doses of an effective amount of at least one HMO for such a use.
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
This invention relates to a method for the enzymatic synthesis of oligosaccharides, preferably human milk oligosaccharides (HMOs) The method comprises the enzymatic transfer of a glycosyl moiety and subsequent removal of by-products, such as lactose, by nanofiltration using a membrane comprising an active polyamide layer.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
It is provided i) an amorphous carbohydrate with improved chemical stability and/or physical features, ii) a method for producing an amorphous carbohydrate with improved chemical stability and/or physical features, and iii) a method for improving the chemical stability and/or the physical features of an amorphous carbohydrate.
A synthetic composition and method for use in providing a source of oligosaccharides to a human consuming a low-FODMAP diet, increasing the abundance of bifidobacteria in the colon of a human consuming a low-FODMAP diet, and/or reintroducing FODMAPs into the diet of a human consuming a low-FODMAP diet. The composition contains one or more human milk oligosaccharides.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The invention relates to a method for the separation of two hydrophilic neutral oligosaccharides from each other with a chromatography on a bromine functionalized polystyrene cross-linked with divinylbenzene (BPS-DVB) stationary medium.
A composition and associated packs and methods for (i) promoting gastrointestinal barrier healing in the upper intestinal tract and/or small intestine of a non-infant human suffering from chronic intestinal barrier inflammation, and/or (ii) maintaining remission in the upper intestinal tract and small intestine of a non-infant human suffering from chronic intestinal barrier inflammation. The composition contains an effective amount of a combination of 6′-sialyllactose (6′-SL) and lacto-N-tetraose (LNT).
The invention relates to a genetically modified microorganism for making an oligosaccharide, preferably of 3-8 monosaccharide units, more preferably of 3-5 monosaccharide units, particularly a HMO, which comprises one or more genes encoding a sucrose utilization system, so the microorganism can use sucrose as a carbon and energy source.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
C12P 19/26 - Preparation of nitrogen-containing carbohydrates
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
49.
Synthetic composition and method for treating irritable bowel syndrome
The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient one or more neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
A23C 9/20 - Dietetic milk products not covered by groups
The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides.
Various methods are provided for providing a solid HMO product, said methods including drum-drying, belt drying, preferably vacuum bed drying, or granulation. Solid HMO products are obtained via said methods, as well as solid HMO products per se. The methods can provide solid HMO products which are different to those achieved via other methods.
F26B 3/20 - Drying solid materials or objects by processes involving the application of heat by conduction, i.e. the heat is conveyed from the heat source, e.g. gas flame, to the materials or objects to be dried by direct contact the heat source being a heated surface
A23C 9/20 - Dietetic milk products not covered by groups
F26B 3/24 - Drying solid materials or objects by processes involving the application of heat by conduction, i.e. the heat is conveyed from the heat source, e.g. gas flame, to the materials or objects to be dried by direct contact the heat source and the materials or objects to be dried being in relative motion, e.g. of vibration the movement being rotation
A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
The invention relates to a method for selective crystallization of 2'-FL from an aqueous solution comprising 2'-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution.
A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.
The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic acid encoding a protein of the MFS superfamily; and methods using said cell for the production the oligosaccharide, preferably an HMO.
C07K 14/24 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic acid encoding a protein of the MFS superfamily; and methods using said cell for the production the oligosaccharide, preferably an HMO.
The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic encoding a putative transporter protein of the MFS superfamily; and methods using said cell for the production of oligosaccharide(s), preferably an HMO.
C07K 14/24 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
57.
NEW MAJOR FACILITATOR SUPERFAMILY (MFS) PROTEIN (BAD) IN HMO PRODUCTION
The present invention relates to the field of recombinant production of biological molecules in genetically modified cells. More particularly, it relates to a method for recombinant production of human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS), the protein expressed being Bad.
The present invention relates to the field of recombinant production of biological molecules in host cells. More particularly it relates to a method for recombinant production of human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS).
The present invention relates to the field of recombinant production of biological molecules in genetically modified cells. More particularly, it relates to a method for recombinant production of human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS), the protein expressed being Fred.
The invention relates to a method, compounds and compositions for the secondary prevention, treatment or dietary management of symptomatic and asymptomatic non-intestinal autoimmune diseases in a non-infant human including Sjogren's syndrome and type 1 diabetes. Said method, compounds and compositions for the secondary prevention, treatment or dietary management include human milk oligosaccharide (HMO), preferably mixtures of human milk oligosaccharides selected from the group of 2′-FL, LNnT, LNT, DFL, and 6′-SL.
Bifidobacterium adolescentis in the non-infant patient by administering the selected effective amount of the selected one or more HMOs and improving in the non-infant patient at least one condition selected from increased insulin sensitivity, reduced insulin resistance, improved gut barrier function, and reduction of metabolic inflammation. In various examples, the method includes increasing levels of at least one glucagon-like peptide.
The present invention relates to the separation and isolation of sialylated human milk oligosaccharides (HMOs) from the reaction mixture in which they are produced.
C07H 5/04 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.
The application relates to compositions containing 2'-FL and DFL for use in a method of reducing pain and/or the perception of visceral pain in a non-infant human.
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in a lactose-intolerant, IBS patient; reintroducing a source of lactose into the diet of a lactose-intolerant, IBS patient while prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in the IBS patient; and/or reducing the severity and/or occurrence of non-gastrointestinal symptoms in a lactose- intolerant, IBS patient.
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in a lactose-intolerant, IBS patient; reintroducing a source of lactose into the diet of a lactose-intolerant, IBS patient while prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in the IBS patient; and/or reducing the severity and/or occurrence of non-gastrointestinal symptoms in a lactose- intolerant, IBS patient.
The invention relates to a human milk oligosaccharide (HMO) for use in supplementing the diet of a pregnant woman, a synthetic composition comprising an HMO for use in supplementing the diet of a pregnant woman, and a method for improving health outcomes in an infant by supplementing the diet of a pregnant woman.
This invention relates to a method and composition for balancing the bile acid profile in the intestine of humans, particularly decreasing primary bile acids and/or increasing production of secondary bile acids.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
This invention relates to a method and composition for balancing the bile acid profile in the intestine of humans, particularly decreasing primary bile acids and/or increasing production of secondary bile acids.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The invention relates to a synthetic composition comprising human milk oligosaccharides for use in at least partially restoring the commensal gastrointestinal microbiota and preventing or mitigating antibiotic associated diarrhoea.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
The present invention relates to the field of recombining production of biological molecules in host cells. The invention provides nucleic acid constructs that allow to modify expression of a desired gene using both in vitro and in vivo gene expression systems. The constructs can advantageously be used to produce a variety of biological molecules recombinantly in industrial scales, e.g. human milk oligosaccharides (HMO).
The present invention relates to the separation and isolation of neutral human milk oligosaccharides (HMOs) from the reaction milieu in which they are produced, preferably from a fermentation broth, comprising the steps of: i) optionally, centrifugation, microfiltration of the reaction milieu, or filtration of the reaction milieu on a filter press or a drum filter to obtain a pre-treated reaction milieu, ii) setting the pH of the pre-treated reaction milieu from step i) or the reaction milieu directly to 3-6 and optionally warming up the pre-treated reaction milieu from step i) or the reaction milieu directly to 35-65 [deg]C, and iii) contacting the reaction milieu obtained in step ii) to an ultrafiltration (UF) membrane with a molecular weight cut-off (MWCO) of 5-1000 kDa and collecting the permeate with the proviso that when step i) is not carried out, then the UF membrane is a non-polymeric membrane.
A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.
Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 9/00 - Medicinal preparations characterised by special physical form
75.
Composition comprising HMOs for preventing or reducing nociception
The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human. The human is administered a composition comprising 6′-sialyllactose (6′-SL) and/or lacto-N-tetraose (LNT).
A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.
B. pseudocatenulatum; for treating or preventing in said non-infant human with type 2 diabetes and/or obesity; an enteropathogenic infection; impaired gut barrier function and/or; an inflammation related to gastro¬intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO. The HMOs comprises 2′-fucosyllactose (preferred), 2′-fucosyllactose (preferred), 3-fucosyllactose, difucosyllactose (preferred), lacto-N-fucopentaose, fucosyl-lacto-N-hexaose, fucosyl-para-lacto-N-hexaose, lacto-N-tetraose (preferred), lacto-N-neotetraose (preferred), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose and para-lacto-N-neohexaose.
The present invention relates to the field of recombinant production of biological molecules in host cells. The invention provides nucleic acid constructs that allow to modify expression of a desired gene using both in vitro and in vivo gene expression systems with optimized stem-loop structures in the 5' UTR of said genes. The constructs can advantageously be used to produce a variety of biological molecules recombinantly in industrial scales, e.g. human milk oligosaccharides (HMOs)
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing, managing or treating postdrome symptoms of migraine, and/or abdominal migraine, and/or the secondary prevention of stress/anxiety induced migraine.
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for prophylactically reducing symptom severity and/or occurrence in a non-coeliac wheat and/or gluten sensitivity patient, and for reducing the severity and/or occurrence of non-gastrointestinal symptoms in the patient.
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing or treating migraine in a human.
The invention relates to a genetically modified microorganism for making a oligosaccharide, preferably of 3-8 monosaccharide units, more preferably of 3-5 monosaccharide units, particularly a HMO, which comprises one or more genes encoding a sucrose utilization system, so the microorganism can use sucrose as a carbon and energy source.
The invention relates to a human milk oligosaccharide (HMO) for use in reducing or preventing fatigue and/or improving focus or concentration on a mental or physical activity in a human. The invention also relates to a synthetic composition for use, comprising one or more of said HMOs. The invention further relates to a method for reducing or preventing fatigue and/or improving focus or concentration on a mental or physical activity by administering at least one HMO and the use of said one or more HMOs in a dietary management of a human.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
The application relates to synthetic compositions containing one or more human milk oligosaccharides for treating serotonin and/or tryptophan dysregulation.
The invention relates to crystalline polymorphs of lacto-N-tetraose (LNT) and methods for making the same for use in pharmaceutical compositions, nutritional formulations and food supplements.
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
86.
HUMAN MILK OLIGOSACCHARIDES AND SYNTHETIC COMPOSITIONS THEREOF FOR MICROBIOTA MODULATION
The present invention relates to methods, compounds and compositions for modulating the microbiota in the gastro-intestinal tracts of humans, particularly for increasing the abundance of Akkermansia in the gut microbiota of humans.
A mixture of human milk oligosaccharides that consists essentially of 6′-SL, LNnT and LSTc, made by treating 6′-SL and LNnT in the presence of an α2,6-transsialidase.
C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
The invention relates to a method for selective crystallization of 2′-fucosyllactose (2′-FL) from an aqueous solution comprising 2′-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution. The aqueous solution is separated from an aqueous culture medium prior to crystallization.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
Use of a human milk oligosaccharide (HMO), or a nutritional composition comprising a human milk oligosaccharide, to enhance executive function in a non-infant, to prevent and/or reduce the risk of sub- optimal executive function in a non-infant, to manage sub-optimal executive functioning in a non-infant, and/or to improve myelination to mature the pre -frontal cortex region of the brain in a non-infant, as well as synthetic compositions of HMOs and packs comprising at least 14 individual daily doses of an effective amount of at least one HMO for such a use.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
It is provided i) an amorphous carbohydrate with improved chemical stability and/or physical features, ii) a method for producing an amorphous carbohydrate with improved chemical stability and/or physical features, and iii) a method for improving the chemical stability and/or the physical features of an amorphous carbohydrate.
This invention relates to a method for the enzymatic synthesis of oligosaccharides, preferably human milk oligosaccharides (HMOs) The method comprises the enzymatic transfer of a glycosyl moiety and subsequent removal of by-products, such as lactose, by nanofiltration using a membrane comprising an active polyamide layer.
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
This invention relates to a method and composition for inducing allergen tolerance in a patient suffering from an atopic allergy or allergic asthma; hence reducing allergy symptoms in these patients.
The invention relates to a method for the separation of two hydrophilic neutral oligosaccharides from each other with a chromatography on a bromine functionalized polystyrene cross-linked with divinylbenzene (BPS-DVB) stationary medium.
A composition and associated packs and methods for (i) promoting gastrointestinal barrier healing in the upper intestinal tract and/or small intestine of a non-infant human suffering from chronic intestinal barrier inflammation, and/or (ii) maintaining remission in the upper intestinal tract and small intestine of a non-infant human suffering from chronic intestinal barrier inflammation. The composition contains an effective amount of a combination of 6'-sialyllactose (6'-SL) and lacto-N-tetraose (LNT).
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
96.
COMPOSITION AND METHOD FOR TREATING HUMANS USING LOW-FODMAP DIETS
A synthetic composition and method for use in providing a source of oligosaccharides to a human consuming a low-FODMAP diet, increasing the abundance of bifidobacteria in the colon of a human consuming a low-FODMAP diet, and/or reintroducing FODMAPs into the diet of a human consuming a low-FODMAP diet. The composition contains one or more human milk oligosaccharides.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemicals for use in industry; biological preparations for
use in industry and science; adjuvants, other than for
medical or veterinary purposes; albumin [animal or
vegetable, raw material]; antioxidants for use in the
manufacture of pharmaceuticals; antioxidants for use in the
manufacture of food supplements; biological preparations,
other than for medical or veterinary purposes; casein for
the food industry; chemical substances for preserving
foodstuffs; cultures of microorganisms, other than for
medical and veterinary use; enzyme preparations for the food
industry; enzymes for the food industry; fatty acids;
gelatine for industrial purposes; glucose for the food
industry; gluten for the food industry; lactose for the food
industry; lecithin for the food industry; milk ferments for
the food industry; pectin for the food industry; proteins
for use in manufacture; proteins for use in the manufacture
of food supplements; proteins for the food industry;
saccharin; sodium; starch for industrial purposes; vitamins
for use in the manufacture of food supplements; vitamins for
the food industry; vitamins for use in the manufacture of
pharmaceuticals; human milk oligosaccharide (HMO)
preparations for use in industry and as raw material, not
for medical use; human milk oligosaccharide (HMO) additives
for pharmaceuticals, nutraceuticals, infant formula,
foodstuffs and animal foods; human milk oligosaccharide
compounds, chemical and biological derivatives of human milk
oligosaccharide compounds and chemical and biological
precursors of human milk oligosaccharide compounds for the
food industry; human milk oligosaccharide compounds,
chemical and biological derivatives of human milk
oligosaccharide compounds and chemical and biological
precursors of human milk oligosaccharide compounds for
scientific use (other than for medical or veterinary use);
human milk oligosaccharide compounds, chemical and
biological derivatives of human milk oligosaccharide
compounds and chemical and biological precursors of human
milk oligosaccharide compounds for industrial use; human
milk oligosaccharide compounds, chemical and biological
derivatives of human milk oligosaccharide compounds and
chemical and biological precursors of human milk
oligosaccharide compounds for use in the manufacture of
pharmaceuticals, nutraceuticals, infant formula, foodstuffs
and animal foods; chemicals additives for use in the
manufacture of dietary supplements and infant formula;
industrial chemicals; oligosaccharides for use in foods;
carbohydrates for use in food manufacture; proteins for use
in food manufacture; oligosaccharides for use in the foods
industry; carbohydrates for use in the foods industry;
proteins for use in the foods industry. Dietetic food and substances adapted for medical or
veterinary use, food for babies; dietary supplements for
human beings and animals; acai powder dietary supplements;
adjuvants for medical purposes; albumin dietary supplements;
albuminous foodstuffs for medical purposes; albuminous
preparations for medical purposes; alginate dietary
supplements; casein dietary supplements; dietary fibre;
dietary supplements for animals; dietetic foods adapted for
medical purposes; dietetic beverages adapted for medical
purposes; dietetic substances adapted for medical use;
enzyme dietary supplements; glucose dietary supplements;
homogenized food adapted for medical purposes; lacteal flour
for babies; linseed dietary supplements; malted milk
beverages for medical purposes; medicated animal feed;
medicinal drinks; milk ferments for pharmaceutical purposes;
lactose for pharmaceutical purposes; mineral food
supplements; nutraceutical preparations for therapeutic or
medical purposes, nutritional supplements; pollen dietary
supplements; powdered milk for babies; protein dietary
supplements; protein supplements for animals; royal jelly
dietary supplements; starch for dietetic or pharmaceutical
purposes, sugar for medical purposes; vitamin preparations;
wheat germ dietary supplements; infant formula; medicated
food additives for humans and for animals; preparations for
use as additives for food for human or animal consumption
(medicated), including vitamin preparations for use as a
supplement for dietary supplements and infant formula; food
supplements for dietetic use; dietary supplements for
medical use; medicated supplements for foodstuffs for
humans, including for infants, and for animals; mineral food
supplements; colostrum supplements; dietary supplemental in
the form of beverages; dietary supplements for infants;
human milk oligosaccharide dietary supplements; human milk
oligo-saccharide compounds for medical purposes; human milk
oligosaccharide additives for use as supplements in
connection with pharmaceuticals, nutraceuticals and infant
formula; human milk oligosaccharide additives for use as a
dietary or nutritional supplement; human milk
oligosaccharide compounds and chemical and biological
derivatives of human milk oligosaccharide compounds for
medical use.
98.
SYNTHESIS OF THE FUCOSYLATED OLIGOSACCHARIDE LNFP-V
The present invention provides a method for biotechnological production of LNFP-V by using recombinant bacterial cells. LNFP-V is produced by using a polypeptide having an a1,3/4-fucosyl transferase activity and comprising or consisting of an amino acid sequence that has a sequence identity of at least 90 % with amino acid sequence of SEQ ID No. 1 or 3.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
The invention relates to a composition comprising one or more human milk oligosaccharides (HMOs) for use in stimulating the production of butyrate in the gastro-intestinal tract of a non-infant human and obtaining delayed increase in the level of butyrate in the gastro-intestinal tract of the non-infant human, and methods for their use.
A method and a composition comprising human milk oligosaccharides for decreasing the production of detrimental proteolytic metabolites such as ammonia and branched chain fatty acids in the intestinal microbiota of humans, which is useful for the treatment of brain-gut disorders like autism, stress, anxiety, and depressive disorders, are disclosed. Methods of treatment of colon cancer and liver damage are also disclosed.
